News from the investment community on July 23, recentlyPharmaceutical Jie Ankang (Nanjing) Technology Co., Ltd. (referred to as "Pharmaceutical Jie Ankang") announced the completion of about US $100 million in D-round financing.This round of financingJointly led by CPE Yuanfeng and Guodian Fund, Sixty Degree Capital, China Merchants Capital, Jinpu Health Fund, Cornerstone Capital and Jiangsu Ruihua follow, including the original shareholders.The funds raised in this round will be used to continue to promote the international development of the pipeline project. China Renaissance Capital Investment serves as the exclusive financial adviser for this round of financing.
Ms. Wu Jing, Executive Director of CPE Yuanfeng, said:Jie Ankang is a small molecule innovative drug research and development company in the clinical stage. At present, four self-developed products have entered the global clinical stage, and many products are the global leaders in their subdivided fields. TT-00420, the first product in the late stage of international clinical development, has a global original biological mechanism, and has the potential to solve the huge unmet clinical needs for refractory and recurrent tumors. We hope that our help can help the company continue to efficiently research and develop more excellent small molecule innovative drugs on the existing platform, become the leader in the research and development of small molecule innovative drugs in China, and work together to meet the needs of the global clinical market. "
Mr. Wei ran, manager and general manager of Chengtong Fund, said:"Pharmaceutical Jie Ankang is a leading small molecule innovative drug research and development company with an international vision. Since its inception, the company has fully demonstrated its vision of international strategic layout, built an international R & D platform and team with original capabilities, and completed a number of international business cooperation, which is a leader in the industry. We very much appreciate the overall R & D platform capability of Jie Ankang in the field of innovation, and hope that we can join hands to help Jie Ankang become a dark horse in the field of small molecule innovative drugs in China, rush to the global market and serve global patients. "
Mr. Xie Yicheng, Managing Director of China Renaissance Capital Investment and head of Medical and Life Technology Group, said:"We are honored to be the long-term partner of Pharmaceutical Jie Ankang since 2018 to assist the company in completing a new round of private equity financing transactions. Jie Ankang has achieved a number of milestones in the short term, and we look forward to the company's continued rapid progress in the future to become a leading international small molecule innovative drug company. "
Dr. Wu Yongqian, Chairman and Chief Executive Officer of Jie Ankang, said:"it is a great honor and thanks to the new and old shareholders for their trust and support. Jie Ankang will continue to take the mission of truly solving the global unmet clinical needs to research and develop new small molecular drugs around the world. This round of financing will help us to continue the global development of innovative drug pipelines and achieve our strategic goals of internationalization and commercialization. "